Background—The goal of this statement is to review available literature and to put forth a
scientific statement on the current practice of fetal cardiac medicine, including the diagnosis …

Background Cell‐free fetal DNA (cff DNA) non‐invasive prenatal testing (NIPT) is rapidly
expanding, and is being introduced at varying rates depending on country and condition …

Non‐invasive prenatal testing (NIPT) for aneuploidy using cell‐free DNA in maternal plasma
is revolutionizing prenatal screening and diagnosis. We review NIPT in the context of …

Objective To evaluate the clinical impact of nationwide implementation of genome‐wide non‐
invasive prenatal testing (NIPT) in pregnancies at increased risk for fetal trisomies 21, 18 …

Background Common fetal aneuploidies include Down syndrome (trisomy 21 or T21),
Edward syndrome (trisomy 18 or T18), Patau syndrome (trisomy 13 or T13), Turner …

Desai AN, Jere A. Next‐generation sequencing: ready for the clinics? Next‐generation
sequencing (NGS) has transformed genomic research by decreasing the cost of sequencing …

The majority of congenital cardiovascular disease including structural cardiac defects,
abnormalities in cardiac function, and rhythm disturbances can be identified prenatally using …

The development of new methods and technologies for cell separation, sorting, selection,
isolation, or enrichment (many times the aforementioned terms are used interchangeably) …

The present disclosure provides methods for determining the ploidy status of a chromosome
in a gestating fetus from genotypic data measured from a mixed sample of DNA comprising …

Fetal DNA is present in the plasma of pregnant women. Massively parallel sequencing of
maternal plasma DNA has been used to detect fetal trisomies 21, 18, 13 and selected sex …